12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xarelto rivaroxaban regulatory update

The U.K.'s NICE issued final guidance recommending the use of Xarelto rivaroxaban from Bayer for the drug's approved indication of treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism (PE) following an acute DVT. The recommendation is in line a...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >